ad

Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low

18 Nov 2026 • 9:43 am

Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low

Amrutanjan Health Care Stock Snapshot (17 Nov 2026 close)

  • Current Market Price (CMP): ₹508.30
  • 52-Week High / Low: ₹725.60 / ₹476.50
  • Market Capitalisation: ₹1,471 crore
  • P/E Ratio vs Industry P/E: 25.7 vs 51.5
  • Latest Quarter (Q2 FY27) Revenue: ₹135.18 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹17.28 crore

Quick Answer: The Amrutanjan analyst review 2027 shows a strong second quarter after a weak first. Q2 FY27 net sales rose about 14.9% to ₹135.18 crore and profit rose about 23.8% to ₹17.28 crore, but H1 profit was ₹21.65 crore, slightly below last year. No named brokerage covers the stock, so there is no published Amrutanjan share price target 2027. At ₹508.30, the stock is about 30% below its 52-week high and close to its low, at a P/E near 25.7, about half its industry level.

The Amrutanjan analyst review 2027 covers the Chennai-based maker of the Amrutanjan pain balm, the Comfy women's hygiene range and Electro+ rehydration drinks. Anyone searching for an Amrutanjan share price target 2027 will not find a dated target from a named research firm, so this review works from results and management guidance.

Amrutanjan Health Care closed at ₹508.30 on 17 November 2026, about 30% below its 52-week high of ₹725.60 and about 7% above its low of ₹476.50. This Amrutanjan analyst review 2027 covers the latest quarter, the brand portfolio and the Amrutanjan stock outlook 2027.

Click Here – Get Free Investment Predictions

What Analysts Say in the Amrutanjan Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

No dated brokerage report with a rating and target on Amrutanjan could be traced. Domestic institutions cut their stake to 6.90% from 12.90% during the year, and foreign investors hold about 3.5%, so research interest is limited.

That shapes the Amrutanjan analyst review 2027. Management guidance carries more weight than usual. The company has guided to 12% to 15% revenue growth in FY27 and a goal of sustaining about a 12% operating margin. Any target shared without a named, registered source should be treated with caution.

Q2 FY27 Results in the Amrutanjan Analyst Review 2027

Metric Q2 FY27 Q2 FY26 Change
Net Sales ₹135.18 crore ₹117.70 crore +14.85%
Profit Before Tax ₹23.10 crore ₹19.21 crore +20.25%
Net Profit ₹17.28 crore ₹13.96 crore +23.78%
H1 Net Sales ₹238.15 crore ₹211.75 crore +12.47%
H1 Net Profit ₹21.65 crore ₹22.27 crore -2.8%

Q2 FY27 net sales rose about 14.9% to ₹135.18 crore, profit before tax rose about 20% to ₹23.10 crore and net profit rose about 23.8% to ₹17.28 crore. Management said operating margin expanded by about 200 basis points despite cost inflation, helped by better fixed cost absorption.

The first half was weaker. Q1 FY27 profit fell to about ₹4.4 crore from ₹8.3 crore, partly because of lower operating profit and exceptional items. As a result, H1 profit of ₹21.65 crore was slightly below the year before even though H1 sales rose about 12.5%. For the Amrutanjan analyst review 2027, Q2 is a recovery quarter rather than proof of a new trend.

How Amrutanjan Makes Money

  • Pain management: balms, roll-ons and sprays under the Amrutanjan brand, the company's original business. Sales rose about 6.1% in H1 FY27.
  • Women's hygiene: sanitary napkins under the Comfy brand, the fastest-growing category at about 20.5% in H1.
  • Rehydration beverages: Electro+ drinks, which grew about 1% in H1 but fell about 21.4% in Q2.
  • Distribution: sales through chemists, general trade, modern trade and online.

The business carries no debt, with debt to equity at 0.00, and earns a return on equity of about 17%. Category mix is the main driver of margins, which is why the Amrutanjan analyst review 2027 tracks each segment separately.

The mix is shifting. The balm business is mature and grows slowly, but it earns strong margins and funds the newer categories. Women's hygiene is growing quickly from a smaller base and needs marketing spend to build share against larger rivals. Beverages are seasonal and swing more from quarter to quarter. The net effect is that overall growth now depends more on Comfy and on distribution reach, while profit still leans on the balm franchise.

Growth Triggers in the Amrutanjan Analyst Review 2027

  • Women's hygiene growth: Comfy grew about 20.5% in H1 FY27.
  • Chemist expansion: the company plans to build 1,00,000 direct chemist outlets in FY27.
  • Margin gains: operating margin expanded about 200 basis points in Q2.
  • Revenue guidance: 12% to 15% growth targeted for FY27, with H1 at about 12.5%.
  • Debt-free balance sheet: no borrowings and steady dividends, a base in the Amrutanjan analyst review 2027.

Key Risks in the Amrutanjan Analyst Review 2027

  • Weak first half: H1 FY27 profit was slightly below last year.
  • Beverage slowdown: rehydration sales fell about 21.4% in Q2.
  • Slow core growth: pain management grew only about 6% in H1.
  • Cost inflation: rising input costs can squeeze margins.
  • Domestic selling: domestic institutions halved their stake to 6.90% from 12.90%.
  • No research coverage: no named targets to anchor expectations.

Compare Amrutanjan Health Care With FMCG and OTC Stocks on the Univest Screener

Amrutanjan Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (17 Nov 2026 close) ₹508.30
52-Week High / Low ₹725.60 / ₹476.50
Market Capitalisation ₹1,471 crore
P/E (TTM) vs Industry 25.7 vs 51.5
Price to Book 3.83
Book Value per Share ₹132.80
Return on Equity 17.07%
Debt to Equity 0.00
Dividend Yield 0.96%
EPS (TTM) ₹19.82

A P/E near 25.7 is about half the industry figure of about 51.5, while price to book value is about 3.8. For a debt-free consumer health company with a 17% return on equity, the Amrutanjan analyst review 2027 points to a valuation that reflects slow growth in the core balm business.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 46.52% 46.52% No change
Foreign Investors (FII) 2.38% 3.47% +1.09 pts
Domestic Institutions (DII) 12.90% 6.90% -6.00 pts
Public 38.20% 43.11% +4.91 pts

The promoter group, led by Goodhealth Holdings at 20.15% and Sambhuprasad Sivalenka at 10.34%, holds a steady 46.52%. Domestic institutions sold six percentage points, which helps explain the price fall. That selling is the biggest ownership shift in the Amrutanjan analyst review 2027 period.

Univest iOS App

Univest Android App

What to Watch After the Amrutanjan Analyst Review 2027

  • H2 growth: whether sales growth reaches the 12% to 15% guided range for the full year.
  • Margins: progress towards the 12% operating margin goal.
  • Comfy momentum: whether women's hygiene keeps growing near 20%.
  • Beverage recovery: Electro+ sales after a 21% fall in Q2.
  • Research coverage: a named note would provide an Amrutanjan share price target 2027 reference.

Final Word on the Amrutanjan Analyst Review 2027

The Amrutanjan analyst review 2027 shows a debt-free consumer health company that bounced back in Q2 FY27, with sales up about 15% and profit up about 24%. A weak Q1 left H1 profit slightly lower, and domestic funds have sold.

The Amrutanjan stock outlook 2027 depends on hygiene growth, a recovery in beverages and margins moving towards 12%. The stock trades at about half its industry P/E. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Amrutanjan analyst review 2027 show?

It shows a strong Q2 after a weak Q1, with no named research coverage. Q2 FY27 net sales rose about 14.9% to ₹135.18 crore and profit rose about 23.8% to ₹17.28 crore. H1 profit of ₹21.65 crore was slightly below last year.

Is there an Amrutanjan share price target 2027 from brokerages?

No dated brokerage target could be verified as of November 2026. Management has guided to 12% to 15% revenue growth for FY27. The stock closed at ₹508.30 on 17 November 2026.

Which Amrutanjan segments are growing fastest?

Women's hygiene under the Comfy brand grew about 20.5% in H1 FY27. Pain management grew about 6.1%. Rehydration drinks grew about 1% in H1 but fell about 21.4% in Q2.

Why was Amrutanjan's H1 profit lower despite higher sales?

Q1 FY27 profit fell to about ₹4.4 crore from ₹8.3 crore because of lower operating profit and exceptional items. Q2 profit recovered to ₹17.28 crore. H1 sales still rose about 12.5% to ₹238.15 crore.

Is Amrutanjan expensive, based on the Amrutanjan analyst review 2027?

The P/E of about 25.7 is about half the industry figure of about 51.5. Price to book is about 3.8 and return on equity is about 17%. The company has no debt.

What risks does the Amrutanjan analyst review 2027 highlight?

The main risks are a weak first half, a fall in beverage sales and slow growth in pain balms. Domestic institutions cut their stake to 6.90% from 12.90%. Input cost inflation can also hurt margins.

What should investors track after the Amrutanjan analyst review 2027?

Track full-year sales against the 12% to 15% guidance and margins against the 12% goal. Watch Comfy growth and any recovery in Electro+. A first named brokerage note would add a reference point.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down